Medibank Private (ASX:MPL) Could Be 25% Overvalued On Osara Health Cancer Care Deal

Medibank Private (ASX:MPL) just moved further into supportive care by partnering with Osara Health to offer its Cancer Coach program to more than 4 million eligible members from 14 October 2026.

While Medibank Private is expanding its care offering with Osara Health, the A$4.74 share price has seen mixed momentum. The 30 day share price return of 2.60% is set against a 90 day decline of 7.60%, and a 5 year total shareholder return of 67.43% that points to a much stronger longer term record.

Scan beyond Medibank Private and see how other health and insurance players are positioning around patient support and solid fundamentals through our curated list of list of solid balance sheet and fundamentals (12 results)

Medibank Private has a new cancer care partnership in play, yet the A$4.74 share price sits between a modest discount to analyst targets and a far deeper intrinsic gap. Where does fair value realistically land within that range?

Most Popular Narrative: 24.7% Overvalued

Medibank Private is trading at A$4.74 against a widely followed narrative fair value closer to A$3.80, which frames the current cancer care expansion against a richer starting point than some investors might expect.

Operative call: WATCH at A$5.00. Accumulate-below tiers: start ~A$3.80 (approximately 15%+ discount to IV, approximately 6% grossed-up yield); full conviction below approximately A$3.40 (25%+ discount). Binding constraint: price / margin of safety. The business clears quality but the entry does not.

See why 4 investors see Medibank Private as 25% overvalued.

Result: Fair Value of A$3.80 (OVERVALUED)

Still, the Medibank Private story could shift quickly if cyber-related penalties bite harder than expected, or if regulators restrict premium increases to levels below claims inflation.

Find out about the key risks to this Medibank Private narrative.

Another View On Medibank Private’s Valuation

On earnings, Medibank Private screens a little differently. The stock trades on a P/E of 20.4x, which is lower than the peer average of 23.7x, yet higher than the global insurance group on 11.3x and above a fair ratio of 19.3x that the market could eventually lean toward.

That mix points to some valuation support relative to local peers, but it also leaves limited room for error if sentiment rotates toward the lower fair ratio or global benchmarks. The question then becomes how much risk an investor is comfortable taking on for a quality profile priced this way.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals around Medibank Private’s price and quality can feel messy, so move quickly, test the data yourself, and pressure test both the upside and the weak spots through the 3 key rewards and 1 important warning sign.

Looking for more ideas beyond Medibank Private?

If Medibank Private has you thinking harder about price, quality and risk, do not stop here. Broaden your watchlist now with a few targeted ideas.

• Target dependable compounding potential by scanning companies with resilient payouts and strong coverage through the 4 dividend fortresses.
• Hunt for mispriced opportunity by filtering for financially healthy businesses that look out of sync with fundamentals using the 4 high quality undervalued stocks.
• Spot future leaders early by tracking lesser known companies with robust metrics through the 15 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com